UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Variations in the FRA10AC1 Fragile Site and 15q21 Are Associated with Cerebrospinal Fluid Aβ1-42 Level

PloS one, 2015-08, Vol.10 (8), p.e0134000-e0134000

2015

Volltextzugriff (PDF)

The ADAS-Cog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials

Alzheimer's & dementia, 2013-02, Vol.9 (1), p.S21-S31

2013

Volltextzugriff (PDF)

Population Pharmacokinetics of Doripenem Based on Data from Phase 1 Studies with Healthy Volunteers and Phase 2 and 3 Studies with Critically Ill Patients

Antimicrobial Agents and Chemotherapy, 2010-06, Vol.54 (6), p.2354-2359

2010

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic-Model-Guided Doripenem Dosing in Critically Ill Patients

Antimicrobial Agents and Chemotherapy, 2010-06, Vol.54 (6), p.2360-2364

2010

Volltextzugriff (PDF)

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

BMC psychiatry, 2012-03, Vol.12 (1), p.26-26, Article 26

2012

Volltextzugriff (PDF)

Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia: A Novel Once-Monthly, Long-Acting Formulation of an Atypical Antipsychotic

Clinical pharmacokinetics, 2009-01, Vol.48 (9), p.585-600

2009

Volltextzugriff (PDF)

Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose‐ranging study

Clinical obesity, 2021-04, Vol.11 (2), p.n/a

2021

Volltextzugriff (PDF)

Quantifying the pathophysiological timeline of Alzheimer's disease

Journal of Alzheimer's disease, 2011-01, Vol.26 (4), p.745-753

2011

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations

Journal of clinical psychopharmacology, 2019-11, Vol.39 (6), p.567-574

2019

Volltextzugriff (PDF)

Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program

Clinical pharmacology and therapeutics, 2024-08, Vol.116 (2), p.282-288

2024

Volltextzugriff (PDF)

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study

Journal of clinical pharmacology, 2016-03, Vol.56 (3), p.330-339

2016

Volltextzugriff (PDF)

An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative

Journal of clinical pharmacology, 2012-05, Vol.52 (5), p.629-644

2012

Volltextzugriff (PDF)

Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I)

European journal of drug metabolism and pharmacokinetics, 2024-07, Vol.49 (4), p.477-489

2024

Volltextzugriff (PDF)

Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post–Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study)

The American heart journal, 2019-07, Vol.213, p.97-104

2019

Volltextzugriff (PDF)

Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose‐ranging study

Clinical obesity, 2021-04, Vol.11 (2), p.n/a

2021

Volltextzugriff (PDF)

Betamethasone pharmacokinetics after two prodrug formulations in sheep: implications for antenatal corticosteroid use

Drug metabolism and disposition, 2005-08, Vol.33 (8), p.1124-1130

2005

Volltextzugriff (PDF)

Dosing and Switching Strategies for Paliperidone Palmitate: Based on Population Pharmacokinetic Modelling and Clinical Trial Data

CNS drugs, 2011-10, Vol.25 (10), p.829-845

2011

Volltextzugriff (PDF)

Quantification of dexamethasone and corticosterone in rat biofluids and fetal tissue using highly sensitive analytical methods: assay validation and application to a pharmacokinetic study

Biomedical chromatography, 2007-06, Vol.21 (6), p.585-597

2007

Volltextzugriff (PDF)

Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia

Clinical pharmacokinetics, 2017-04, Vol.56 (4), p.421-433

2017

Volltextzugriff (PDF)

Pharmacodynamic Profiling of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections

Antimicrobial Agents and Chemotherapy, 2009-08, Vol.53 (8), p.3371-3374

2009

Volltextzugriff (PDF)

Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

Targeted oncology, 2023-09, Vol.18 (5), p.667-684

2023

Volltextzugriff (PDF)

Modeling glucocorticoid-mediated fetal lung maturation: I. Temporal patterns of corticosteroids in rat pregnancy

The Journal of pharmacology and experimental therapeutics, 2006-04, Vol.317 (1), p.117-126

2006

Volltextzugriff (PDF)

Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data

CNS drugs, 2017-04, Vol.31 (4), p.273-288

2017

Volltextzugriff (PDF)

Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia

Current medical research and opinion, 2015-11, Vol.31 (11), p.2043-2054

2015

Volltextzugriff (PDF)

Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes

British journal of clinical pharmacology, 2013-01, Vol.75 (1), p.146-161

2013

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(42)

Publikationsform

Sprache

Englisch
(57)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(40)
Science & Technology
(40)
Pharmacology & Pharmacy
(26)
Humans
(25)
Female
(22)
Male
(16)
Pharmacokinetics
(14)
Aged
(12)
Middle Aged
(11)
Schizophrenia
(11)
Adult
(10)
Alzheimer's Disease
(9)
Animals
(9)
Biological And Medical Sciences
(9)
Medical Sciences
(9)
Models, Biological
(9)
Neurosciences & Neurology
(9)
Paliperidone Palmitate
(9)
Pharmacology. Drug Treatments
(9)
Antipsychotic Agents - Administration & Dosage
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Variations in the FRA10AC1 Fragile Site and 15q21 Are Associated with Cerebrospinal Fluid Aβ1-42 Level

The ADAS-Cog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials

Population Pharmacokinetics of Doripenem Based on Data from Phase 1 Studies with Healthy Volunteers and Phase 2 and 3 Studies with Critically Ill Patients

Pharmacokinetic-Pharmacodynamic-Model-Guided Doripenem Dosing in Critically Ill Patients

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia: A Novel Once-Monthly, Long-Acting Formulation of an Atypical Antipsychotic

Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose‐ranging study

Quantifying the pathophysiological timeline of Alzheimer's disease

Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations

Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study

An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative

Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I)

Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post–Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study)

Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose‐ranging study

Betamethasone pharmacokinetics after two prodrug formulations in sheep: implications for antenatal corticosteroid use

Dosing and Switching Strategies for Paliperidone Palmitate: Based on Population Pharmacokinetic Modelling and Clinical Trial Data

Quantification of dexamethasone and corticosterone in rat biofluids and fetal tissue using highly sensitive analytical methods: assay validation and application to a pharmacokinetic study

Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia

Pharmacodynamic Profiling of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections

Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

Modeling glucocorticoid-mediated fetal lung maturation: I. Temporal patterns of corticosteroids in rat pregnancy

Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data

Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia

Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes

Suchergebnisse filtern